BIOMED REALTY TRUST, INC. Shares of Common Stock (par value $0.01 per share) EQUITY DISTRIBUTION AGREEMENT
Exhibit 1.3
BIOMED REALTY TRUST, INC.
$120,000,000
Shares of Common Stock
(par value $0.01 per share)
Dated: September 4, 2009
Table of Contents
Page | ||||
SECTION 1. Description of Securities |
1 | |||
SECTION 2. Placements |
2 | |||
SECTION 3. Sale of Placement Securities by Xxxxx Fargo Securities |
3 | |||
SECTION 4. Suspension of Sales |
3 | |||
SECTION 5. Representations and Warranties |
4 | |||
SECTION 6. Sale and Delivery to Xxxxx Fargo Securities; Settlement |
20 | |||
SECTION 7. Covenants of the Company |
22 | |||
SECTION 8. Payment of Expenses |
27 | |||
SECTION 9. Conditions of Xxxxx Fargo Securities’ Obligations |
28 | |||
SECTION 10. Indemnification |
30 | |||
SECTION 11. Contribution |
32 | |||
SECTION 12. Representations, Warranties and Agreements to Survive Delivery |
33 | |||
SECTION 13. Termination of Agreement |
34 | |||
SECTION 14. Notices |
35 | |||
SECTION 15. Parties |
35 | |||
SECTION 16. Adjustments for Stock Splits |
35 | |||
SECTION 17. Governing Law and Time |
35 | |||
SECTION 18. Effect of Headings |
35 | |||
SECTION 19. Definitions |
35 | |||
SECTION 20. Permitted Free Writing Prospectuses |
36 | |||
SECTION 21. Absence of Fiduciary Relationship |
37 |
i
EXHIBITS
Exhibit A
|
— | Form of Placement Notice | ||
Exhibit B
|
— | Authorized/Designated Individuals for Placement Notices | ||
Exhibit C
|
— | Compensation | ||
Exhibit D
|
— | Subsidiaries of the Company | ||
Exhibit E-1
|
— | Form of Opinion of Company Counsel | ||
Exhibit E-2
|
— | Form of Opinion of Company Tax Counsel | ||
Exhibit E-3
|
— | Form of Opinion of Company Special Maryland Counsel | ||
Exhibit F
|
— | Officer Certificate | ||
Exhibit G
|
— | Issuer Free Writing Prospectus |
ii
BioMed Realty Trust, Inc.
$120,000,000
Shares of Common Stock
(par value $0.01 per share)
Shares of Common Stock
(par value $0.01 per share)
September 4, 2009
Xxxxx Fargo Securities, LLC
000 Xxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
000 Xxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
BioMed Realty Trust, Inc., a Maryland corporation (the “Company”), and BioMed Realty,
L.P., a Maryland limited partnership (the “Operating Partnership” and together with the
Company, the “Transaction Entities”), each confirms its agreement (this
“Agreement”) with Xxxxx Fargo Securities, LLC (“Xxxxx Fargo Securities”), as
follows:
SECTION 1. Description of Securities.
Each of the Transaction Entities agrees that, from time to time during the term of this
Agreement, on the terms and subject to the conditions set forth herein, the Company may issue and
sell through or to Xxxxx Fargo Securities, acting as agent and/or principal, shares (the
“Securities”) of the Company’s common stock, par value $0.01 per share (the “Common
Stock”) having an aggregate offering price of up to $120,000,000 (the “Maximum
Amount”). The Company agrees that if it determines that Xxxxx Fargo Securities will purchase
any Securities on a principal basis, then it will enter into a separate underwriting or similar
agreement in form and substance satisfactory to both the Company and Xxxxx Fargo Securities
covering such purchase. Notwithstanding anything to the contrary contained herein, the parties
hereto agree that compliance with the limitations set forth in this Section 1 regarding the
aggregate offering price of the Securities issued and sold under this Agreement shall be the sole
responsibility of the Company, and Xxxxx Fargo Securities shall have no obligation in connection
with such compliance. The issuance and sale of the Securities through Xxxxx Fargo Securities will
be effected pursuant to the Registration Statement (as defined below) filed by the Company and
declared effective by the Securities and Exchange Commission (the “Commission”), although
nothing in this Agreement shall be construed as requiring the Company to use the Registration
Statement to issue the Securities. The Transaction Entities hereby reserve the right to issue and
sell securities other than through or to Xxxxx Fargo Securities during the term of this Agreement
subject to the notice provision contained in Section 7(k) herein.
The Company has filed, in accordance with the provisions of the Securities Act of 1933, as
amended (the “Securities Act”) and the rules and regulations thereunder (the
“Securities Act Regulations”), with the Commission a registration statement on Form S-3
(File No. 333-161751), including a base prospectus, relating to certain securities, including the
Securities to be issued
1
from time to time by the Company, and which incorporates by reference documents that the
Company has filed or will file in accordance with the provisions of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), and the rules and regulations thereunder (the
“Exchange Act Regulations”). The Company has prepared a prospectus supplement specifically
relating to the Securities (the “Prospectus Supplement”) to the base prospectus included as
part of such registration statement. The Company will furnish to Xxxxx Fargo Securities, for use
by Xxxxx Fargo Securities, copies of the prospectus included as part of such registration
statement, as supplemented by the Prospectus Supplement, relating to the Securities. Except where
the context otherwise requires, such registration statement, as amended when it became effective,
including all documents filed as part thereof or incorporated by reference therein, and including
any information contained in a Prospectus (as defined below) subsequently filed with the Commission
pursuant to Rule 424(b) under the Securities Act Regulations or deemed to be a part of such
registration statement pursuant to Rule 430B of the Securities Act Regulations, is herein called
the “Registration Statement.” The Registration Statement at the time it originally became
effective is herein called the “Original Registration Statement.” The base
prospectus, including all documents incorporated therein by reference, included in the Registration
Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such
prospectus and/or Prospectus Supplement have most recently been filed by the Company with the
Commission pursuant to Rule 424(b) under the Securities Act Regulations is herein called the
“Prospectus.” Any reference herein to the Registration Statement, the Prospectus or any
amendment or supplement thereto shall be deemed to refer to and include the documents incorporated
by reference therein, and any reference herein to the terms “amend,” “amendment” or “supplement”
with respect to the Registration Statement or the Prospectus shall be deemed to refer to and
include the filing after the execution hereof of any document with the Commission deemed to be
incorporated by reference therein. For purposes of this Agreement, all references to the
Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to
include any copy filed with the Commission via XXXXX (other than in connection with any opinion
given by counsel in Section 7 hereof, which hereby expressly excludes any copy filed via
XXXXX).
The Company has also entered into separate equity distribution agreements (each an
“Alternative Distribution Agreement” and collectively, the “Alternative Distribution
Agreements”), dated as of even date herewith, with each of UBS Securities LLC and Xxxxxxx Xxxxx
& Associates, Inc. (each an “Alternative Manager” and collectively, the “Alternative
Managers”). The aggregate gross sales price of the Securities that may be sold pursuant to
this Agreement and the Alternative Distribution Agreements shall not exceed the Maximum Amount.
SECTION 2. Placements.
Each time that the Company wishes to issue and sell the Securities hereunder (each, a
“Placement”), it will notify Xxxxx Fargo Securities by email notice (or other method
mutually agreed to in writing by the parties) containing the parameters in accordance with which it
desires the Securities to be sold, which shall at a minimum include the number of Securities to be
issued (the “Placement Securities”), the time period during which sales are requested to be
made, any limitation on the number of Securities that may be sold in any one day and any minimum
price below which sales may not be made (a “Placement Notice”), a form of which containing
such minimum sales parameters necessary is attached hereto as Exhibit A. The Placement
Notice
2
shall originate from any of the individuals from the Company set forth on Exhibit B
(with a copy to each of the other individuals from the Company listed on such schedule), and shall
be addressed to each of the individuals from Xxxxx Fargo Securities set forth on Exhibit B,
as such Exhibit B may be amended from time to time. The Placement Notice shall be
effective upon receipt by Xxxxx Fargo Securities, unless and until (i) in accordance with the
notice requirements set forth in the second sentence of this paragraph, Xxxxx Fargo Securities
declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the
entire amount of the Placement Securities have been sold, (iii) in accordance with the notice
requirements set forth in the second sentence of this paragraph, the Company terminates the
Placement Notice, (iv) the Company issues a subsequent Placement Notice with parameters superseding
those on the earlier dated Placement Notice, (v) the Agreement has been terminated under the
provisions of Section 13 or (vi) either party shall have suspended the sale of the Placement
Securities in accordance with Section 4 below. The amount of any discount, commission or other
compensation to be paid by the Company to Xxxxx Fargo Securities in connection with the sale of the
Placement Securities shall be calculated in accordance with the terms set forth in Exhibit
C. It is expressly acknowledged and agreed that neither the Company nor Xxxxx Fargo Securities
will have any obligation whatsoever with respect to a Placement or any Placement Securities unless
and until the Company delivers a Placement Notice to Xxxxx Fargo Securities and Xxxxx Fargo
Securities does not decline the terms of such Placement Notice pursuant to the terms set forth
above, and then only upon the terms specified therein and herein.
SECTION 3. Sale of Placement Securities by Xxxxx Fargo Securities.
Subject to the provisions of Section 6(a), Xxxxx Fargo Securities, for the period specified in
the Placement Notice, will use its commercially reasonable efforts consistent with its normal
trading and sales practices, to sell the Placement Securities up to the amount specified, and
otherwise in accordance with the terms of such Placement Notice. Xxxxx Fargo Securities will
provide written confirmation to the Company no later than the opening of the Trading Day (as
defined below) immediately following the Trading Day on which it has made sales of Placement
Securities hereunder setting forth the number of Placement Securities sold on such day, the
compensation payable by the Company to Xxxxx Fargo Securities pursuant to Section 2 with respect to
such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of
the deductions made by Xxxxx Fargo Securities (as set forth in Section 6(b)) from the gross
proceeds that it receives from such sales. Subject to the terms of the Placement Notice, Xxxxx
Fargo Securities may sell Placement Securities by any method permitted by law deemed to be an “at
the market” offering as defined in Rule 415 of the Securities Act Regulations, including without
limitation sales made directly on the NYSE, on any other existing trading market for the Common
Stock or to or through a market maker. Subject to the terms of a Placement Notice, Xxxxx Fargo
Securities may also sell Placement Securities by any other method permitted by law, including but
not limited to in privately negotiated transactions. For the purposes hereof, “Trading
Day” means any day on which shares of Common Stock are purchased and sold on the principal
market on which the Common Stock is listed or quoted.
SECTION 4. Suspension of Sales. The Company or Xxxxx Fargo Securities may, upon
notice to the other party in writing (including by email correspondence to each of the individuals
of the other party set forth on Exhibit B, if receipt of such correspondence is actually
acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or
3
by telephone (confirmed immediately by verifiable email correspondence to each of the
individuals of the other party set forth on Exhibit B), suspend the sale of Securities
under this Agreement; provided, however, that such suspension shall not affect or impair either
party’s obligations with respect to any Placement Securities sold hereunder prior to the receipt of
such notice. Each of the parties agrees that no such notice under this Section 4 shall be
effective against the other unless it is made to one of the individuals named on Exhibit B
hereto, as such Exhibit may be amended from time to time.
SECTION 5. Representations and Warranties.
(a) Representations and Warranties by the Transaction Entities. Each of the Transaction
Entities, jointly and severally, represents and warrants to Xxxxx Fargo Securities as of the date
hereof and as of each Representation Date on which a certificate is required to be delivered
pursuant to Section 7(o) of this Agreement and as of each Applicable Time, and agrees with Xxxxx
Fargo Securities, as follows:
(1) Status as a Well-Known Seasoned Issuer; Registration Statement Effective; Conform to
Securities Act; No Misleading Statements; Conformity with XXXXX filings. (A) At the time of
filing the Original Registration Statement, (B) at the time the Company or any person acting on its
behalf (within the meaning, for this clause only, of Rule 163(c) of the Securities Act Regulations)
made any offer relating to the Securities in reliance on the exemption of Rule 163 of the
Securities Act Regulations (“Rule 163”) and (C) at the date hereof, the Company (x) was and
is a “well-known seasoned issuer” as defined in Rule 405 of the Securities Act Regulations
(“Rule 405”) and (y) was not and is not an “ineligible issuer,” as defined in Rule 405.
The Registration Statement is an “automatic shelf registration statement,” as defined in Rule 405,
and the Securities, since their registration on the Registration Statement, have been and remain
eligible for registration by the Company on a Rule 405 “automatic shelf registration statement”.
The Company has not received from the Commission any notice pursuant to Rule 401(g)(2) of the
Securities Act Regulations objecting to the use of the automatic shelf registration statement form.
The Company has paid, or if the Prospectus Supplement has not yet been filed with the Commission,
will pay the required Commission filing fees relating to the Securities within the time required by
Rule 456(b)(1)(i) of the Securities Act without regard to the proviso therein and otherwise in
accordance with Rules 456(b) and 457(r) of the Securities Act Regulations (including, if
applicable, by updating the “Calculation of Registration Fee” table in accordance with Rule
456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or on the cover
page of the Prospectus).
At the time of filing the Original Registration Statement, at the earliest time thereafter that the
Company or another offering participant made a bona fide offer (within the meaning of Rule
164(h)(2) of the Securities Act Regulations) of the Securities and at the date hereof, the Company
was not and is not an “ineligible issuer,” as defined in Rule 405.
The Original Registration Statement became effective upon filing under Rule 462(e) of the
Securities Act Regulations (“Rule 462(e)”) on September 4, 2009, and any post-effective
amendment thereto also became effective upon filing under Rule 462(e).
Any offer that is a written communication relating to the Securities made prior to the filing of
the Original Registration Statement by the Company or any person acting on its behalf (within the
4
meaning, for this paragraph only, of Rule 163(c) of the Securities Act Regulations) has been filed
with the Commission in accordance with the exemption provided by Rule 163 and otherwise complied
with the requirements of Rule 163, including without limitation the legending requirement, to
qualify such offer for the exemption from Section 5(c) of the Securities Act provided by Rule 163.
At the respective times the Original Registration Statement, any Registration Statement and any
amendment thereto became effective, at the deemed effective date with respect to Xxxxx Fargo
Securities pursuant to Rule 430B(f)(2) of the Securities Act Regulations, at the date of this
Agreement and at each relevant Settlement Date (as defined in Section 6(b)), the Registration
Statement and any amendments or supplements thereto complied and will comply, in all material
respects with the requirements of the Securities Act and the Securities Act Regulations and did not
and will not contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading; the
Prospectus and any further amendments or supplements thereto, at the time the Prospectus or such
amendment or supplement was issued, at the date hereof, at the time of filing pursuant to Rule
424(b) and at each relevant Settlement Date, complied and will comply, in all material respects
with the requirements of the Securities Act and the Securities Act Regulations and did not, and any
amendment thereto will not, contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading; and each preliminary
prospectus and the prospectus filed as part of the Original Registration Statement as originally
filed or as part of any amendment or supplement thereto or filed pursuant to Rule 424 of the
Securities Act Regulations, complied when so filed in all material respects with the Securities Act
and the Securities Act Regulations. The conditions for the use of Form S-3, as set forth in the
General Instructions thereto, and the Registration Statement meets, and the offering and sale of
the Securities as contemplated hereby complies with, the requirements of Rule 415 of the Securities
Act Regulations (including, without limitation, Rule 415(a)(5)).
Each Issuer Free Writing Prospectus, as of its issue date and as of each Applicable Time and
Settlement Date, or until any earlier date that the issuer notified or notifies Xxxxx Fargo
Securities as described in Section 7(d), did not, does not and will not include any information
that conflicted, conflicts or will conflict with the information contained in the Registration
Statement or the Prospectus, including any document incorporated by reference therein and any
preliminary or other prospectus deemed to be a part thereof that has not been superseded or
modified or, taken together with the Prospectus, included, includes or will include an untrue
statement of a material fact or omitted, omits or will omit to state a material fact necessary in
order to make the statements therein, in light of the circumstances under which they were made, not
misleading.
The representations and warranties in Section 5(a)(1) of this Agreement shall not apply to
statements in or omissions from the Registration Statement, the Prospectus or any Issuer Free
Writing Prospectus made in reliance upon and in conformity with written information furnished to
the Company by Xxxxx Fargo Securities expressly for use therein.
5
Each Prospectus delivered to Xxxxx Fargo Securities and used in connection with this offering
was identical to the electronically transmitted copies thereof filed with the Commission pursuant
to XXXXX, except to the extent permitted by Regulation S-T under the Securities Act.
(2) No Stop Order. No stop order suspending the effectiveness of the Registration
Statement or any part thereof has been issued and no proceeding for that purpose has been
instituted or, to the knowledge of either of the Transaction Entities, threatened by the Commission
or by the state securities authority of any jurisdiction. No order preventing or suspending the
use of the Prospectus or any Permitted Free Writing Prospectus (as defined in Section 20) has been
issued, and no proceeding for that purpose has been instituted or, to the knowledge of either of
the Transaction Entities, threatened by the Commission or by the state securities authority of any
jurisdiction.
(3) Incorporated Documents. Each document incorporated or deemed to be incorporated
by reference in the Prospectus or the Registration Statement (the “Incorporated
Documents”), when such Incorporated Document was filed with the Commission, complied in all
material respects with the requirements of the Securities Act and the Securities Act Regulations or
the Exchange Act and the rules and regulations of the Commission thereunder (the “Exchange Act
Regulations”), as applicable, in effect at the time of the filing, and any further documents so
filed and incorporated after the date of this Agreement up to the later of the termination of this
Agreement or the end of the period in which a prospectus relating to the Securities is required to
be delivered under the Securities Act (whether physically or through compliance with Rule 172 under
the Securities Act Regulations or any similar rule) will, when they are filed, comply in all
material respects with the requirements of the Securities Act and the Securities Act Regulations or
the Exchange Act and Exchange Act Regulations; and each such Incorporated Document when it was
filed did not, or when it is filed will not, as the case may be, contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading.
(4) Company Formation; Good Standing; Qualification. The Company has been duly formed
and is validly existing as a corporation in good standing under the laws of the state of Maryland,
with power and authority (corporate and other) to own its properties and conduct its business as
described in the Prospectus and to enter into and perform its obligations under this Agreement and
as general partner of the Operating Partnership to cause the Operating Partnership to enter into
and perform the Operating Partnership’s obligations under this Agreement, and the Company is duly
qualified to do business as a foreign corporation in good standing in all other jurisdictions in
which its ownership or lease of property or the conduct of its business requires such
qualification, except where the failure to so qualify would not reasonably be expected to have,
individually or in the aggregate, a material adverse effect on the condition (financial or other),
business, earnings, properties, assets, results of operations or prospects of the Transaction
Entities and the Subsidiaries (as defined below) taken as a whole, whether or not in the ordinary
course (“Material Adverse Effect”).
(5) Operating Partnership Formation; Good Standing; Qualification; Interests in Operating
Partnership. The Operating Partnership has been duly formed and is validly existing as a
limited partnership in good standing under the laws of the state of Maryland, is duly
6
qualified to do business and is in good standing as a foreign limited partnership in each
jurisdiction in which its ownership or lease of property or the conduct of its business requires
such qualification, except where the failure to so qualify would not reasonably be expected to have
a Material Adverse Effect, and has all power and authority necessary to own its properties and
conduct its business as described in the Prospectus and to enter into and perform its obligations
under this Agreement. The Company is the sole general partner of the Operating Partnership and
holds the number and/or percentage of units representing limited partnership interests in the
Operating Partnership (“OP Units”) as disclosed in or incorporated by reference in the
Prospectus, as of the dates set forth therein, free and clear of any security interests, liens,
mortgages, encumbrances, pledges, claims, defects or other restrictions of any kind (collectively,
“Liens”). The Fourth Amended and Restated Agreement of Limited Partnership of the
Operating Partnership, as amended (the “Operating Partnership Agreement”) is in full force
and effect. The aggregate percentage interests of the Company and the limited partners in the
Operating Partnership are as set forth in or incorporated by reference in the Prospectus, as of the
dates set forth therein.
(6) Subsidiary Formation; Good Standing; Qualification; Liens; Pre-Emptive Rights.
Each direct or indirect subsidiary of the Company and of the Operating Partnership, all of which
are listed on Exhibit D hereto (each, a “Subsidiary” and together the
“Subsidiaries”), has been duly formed and is validly existing as a corporation, limited
partnership, limited liability company or common law trust, as the case may be, in good standing
under the laws of the jurisdiction of its organization, with power and authority (corporate and
other) to own its assets and conduct its business as described in the Prospectus and to enter into
and to perform its obligations under this Agreement; and is duly qualified to do business as a
foreign corporation, limited partnership or limited liability company, as the case may be, in good
standing in all other jurisdictions in which its ownership or lease of property or the conduct of
its business requires such qualification, except where the failure to so qualify would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; all of
its issued and outstanding capital stock or other ownership interests have been duly authorized and
validly issued and are fully paid and non-assessable; and all outstanding shares of its capital
stock or other ownership interests are owned by the Company or the Operating Partnership, directly
or through the Subsidiaries, free and clear of any Liens, except as described in the Prospectus or
where such Liens would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect. None of the equity interests of any Subsidiary were issued in violation
of the preemptive or other similar rights of any securityholder of such Subsidiary. There are no
outstanding options, rights (preemptive or otherwise) or warrants to purchase or subscribe for
equity interests or other securities of any Subsidiary, except as set forth in the organizational
documents of such Subsidiary.
(7) Capital of the Company; Options; No Preemptive Rights. The authorized, issued and
outstanding Capital Stock of the Company is in all material respects as set forth in the
Prospectus. None of the outstanding shares of Capital Stock of the Company was issued in violation
of the preemptive or other similar rights of any securityholder of the Company. Further, (i)
except for shares of Common Stock reserved for issuance (A) upon exchange or redemption of the OP
Units or long term incentive plan units of the Operating Partnership (the “LTIP Units”),
(B) in connection with the existing BioMed Realty Trust, Inc. and BioMed Realty, L.P. 2004
Incentive Award Plan, as amended and restated effective May 27, 2009 (the
7
“Equity Incentive Plan”), or (C) upon exchange of the Operating Partnership’s 4.50%
Exchangeable Senior Notes due 2026 (the “Exchangeable Notes”), all as disclosed in the
Prospectus, no shares of Common Stock are reserved for any purpose; (ii) except for the OP Units,
LTIP Units and the Exchangeable Notes as disclosed in the Prospectus, there are no outstanding
securities convertible into or exchangeable for any shares of Common Stock; and (iii) except for
the Exchangeable Notes disclosed in the Prospectus and in connection with our investment in one of
our joint ventures, pursuant to which the joint venture party has the right to require the
Operating Partnership to issue OP Units in connection with a put call option, which represents less
than 1% of the Company’s currently outstanding Common Stock, there are no outstanding options,
rights (preemptive or otherwise) or warrants to purchase or subscribe for shares of Common Stock or
any other securities of the Company or of the Operating Partnership.
(8) Authorization of Issuance of Securities; Conformity with Applicable Laws. The
Securities to be sold by the Company pursuant to this Agreement have been duly authorized for
issuance and sale to or through Xxxxx Fargo Securities, and all other outstanding shares of Capital
Stock of the Company have been duly authorized; all outstanding shares of Capital Stock of the
Company are, and, when the Securities have been delivered and paid for in accordance with this
Agreement, such Securities will have been, validly issued, fully paid and non-assessable, have
been, or will be, offered and sold in compliance with all applicable federal and state securities
laws and will conform in all material respects to the description thereof contained in the
Prospectus. Upon payment of the purchase price and delivery of the Securities in accordance
herewith, the purchasers will receive good, valid and marketable title to the Securities, free and
clear of all Liens. The form of the certificates, if any, to be used to evidence the Securities
will be in substantially the form filed or incorporated by reference as an exhibit to the
Registration Statement, is in due and proper form and complies with all applicable legal
requirements, the requirements of the charter and bylaws of the Company and the requirements of the
New York Stock Exchange, Inc. (the “NYSE”).
(9) Authorization of Issuance of OP Units; Conformity with Applicable Laws; No Preemptive
Rights. The issued and outstanding OP Units and Series A preferred units of limited
partnership interest in the Operating Partnership have been duly authorized for issuance by the
Operating Partnership to the holders thereof and are validly issued, fully paid and non-assessable,
have been offered and sold or exchanged by the Operating Partnership in compliance with applicable
laws and conform in all material respects to the description thereof contained in the Prospectus.
The OP Units to be issued to the Company in connection with the offering contemplated by this
Agreement have been duly authorized for issuance by the Operating Partnership and, when issued and
delivered by the Operating Partnership to the Company in connection with the contribution of the
net proceeds of the offering, will be validly issued, fully paid and non-assessable. The OP Units
will be exempt from registration or qualification under the Securities Act and applicable state
securities laws. None of the OP Units will be subject to or issued in violation of the preemptive
or other similar rights of any securityholder of the Operating Partnership.
(10) No Other Brokerage Fees. Except as disclosed in the Prospectus, there are no
contracts, agreements or understandings between the Transaction Entities, any Subsidiary and any
person that would give rise to a valid claim against the Transaction Entities, any Subsidiary,
8
or Xxxxx Fargo Securities for a brokerage commission, finder’s fee or other like payment in
connection with this offering.
(11) No Registration Rights. Except for the Registration Rights Agreements entered
into in connection with the Company’s initial public offering by and among the Company, the
Operating Partnership and the holders of OP Units party thereto dated as of August 13, 2004, as
amended (the “Unitholder Registration Rights Agreements”), the Registration Rights
Agreement entered into in connection with the issuance of the Exchangeable Notes by and among the
Company and the initial purchasers of the Exchangeable Notes dated as of September 25, 2006 (the
“Notes Registration Rights Agreement”) and the Registration Rights Agreement
entered into in connection with the formation of BMR-PR II LLC by and between the Company and the
Prudential Insurance Company of America dated as of April 4, 2007 (the “JV Registration Rights
Agreement”), there are no contracts, agreements or understandings between the Transaction
Entities and any person granting such person the right to require the Transaction Entities to file
a registration statement under the Securities Act with respect to any securities of the Transaction
Entities owned or to be owned by such person. There are no contracts, agreements or understandings
between the Transaction Entities and any person granting such person the right to require the
Transaction Entities to include such securities in the securities registered pursuant to the
Registration Statement.
(12) No Violations or Defaults. None of the Transaction Entities nor the
Subsidiaries, (i) is in violation of its charter or by-laws or other similar organizational
documents, (ii) is in default (whether with or without the giving of notice or passage of time or
both) in the performance or observance of any obligation, agreement, term, covenant or condition
contained in a contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease
(under which such Transaction Entity or a Subsidiary is landlord or otherwise), ground lease or air
space lease (under which such Transaction Entity or a Subsidiary is tenant), development agreement,
reciprocal easement agreement, deed restriction, hotel management agreement, parking management
agreements, or other agreement or instrument to which it is a party or by which it or any of them
is a party or may be bound, or to which any of the Properties (as hereinafter defined) or any of
the property or assets of such Transaction Entity or Subsidiary is subject (collectively,
“Agreements or Instruments”), or (iii) is in violation of any law, ordinance, governmental
rule, regulation or court decree to which it or the Properties or any of its other properties or
assets may be subject, except for such defaults or violations that would not have, individually or
in the aggregate, a Material Adverse Effect.
(13) No Consents Required. No consent, approval, authorization, or order of, or
filing or registration with, any governmental agency or body or any court or any third party is
required for the consummation of the transactions contemplated by this Agreement, except as have
been obtained or made under the Securities Act and as may be required under state securities laws
or the rules of FINRA or that the absence of which would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect.
(14) Non-Contravention. Except as disclosed in the Prospectus, the execution,
delivery and performance of this Agreement by the Transaction Entities and the consummation of the
transactions contemplated hereby (including the issuance and sale of the Securities and the use of
the proceeds from the sale of the Securities as described in the Prospectus under “Use of
9
Proceeds”) do not and will not (whether with or without the giving of notice or passage of time or
both) conflict with or result in a breach or violation of any of the terms and provisions of, or
constitute a default (or give rise to any right of termination, acceleration, cancellation,
repurchase or redemption) or Repayment Event (as hereinafter defined) under, or result in the
creation or imposition of a Lien upon any property or assets of the Transaction Entities or any
Subsidiary pursuant to, (i) any statute, any rule, regulation or order of any governmental agency
or body or any court, domestic or foreign, having jurisdiction over the Transaction Entities or any
of the Subsidiaries or any of their properties, assets or business currently owned by them; (ii)
any term, condition or provision of any Agreements or Instruments; or (iii) the charters, by-laws
or other organizational documents, as applicable, of the Transaction Entities or any of the
Subsidiaries, except for such conflicts, breaches, violations or defaults that (with respect to
subclauses (i) and (ii) above) would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. As used herein, “Repayment Event” means any event or
condition which, without regard to compliance with any notice or other procedural requirements,
gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on
such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a
portion of such indebtedness by the Company, the Operating Partnership or any Subsidiary.
(15) Validity and Sufficiency of Agreements. This Agreement has been duly and validly
authorized, executed and delivered by each of the Transaction Entities party thereto, and the
Operating Partnership Agreement is a valid and binding agreement of each of the Transaction
Entities that are parties thereto, enforceable against such Transaction Entity in accordance with
its terms, except (i) to the extent that such enforceability may be limited by applicable
bankruptcy, insolvency, fraudulent transfer, moratorium, reorganization or other similar laws now
or hereafter in effect relating to or affecting creditors’ rights; (ii) as limited by the effect of
general principles of equity, whether enforcement is considered in a proceeding in equity or at law
(including the possible unavailability of specific performance or injunctive relief), concepts of
materiality, reasonableness, good faith and fair dealing, and the discretion of the court before
which any proceeding therefore may be brought; (iii) the unenforceability under certain
circumstances under law or court decisions of provisions providing for the indemnification of or
contribution to a party with respect to a liability where such indemnification or contribution is
contrary to public policy; and (iv) the unenforceability of any provision requiring the payment of
attorney’s fees, except to the extent that a court determines such fees to be reasonable.
(16) Licenses. The Transaction Entities and the Subsidiaries possess adequate
certificates, authorities, licenses, consents, approvals, permits and other authorizations
(“Licenses”) issued by appropriate governmental agencies or bodies or third parties
necessary to conduct the business now operated by them, have maintained such Licenses in full force
and effect, and have not received any notice of proceedings relating to the revocation or
modification of any such Licenses that, if determined adversely to the Transaction Entities or any
of the Subsidiaries, would reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect. The Transaction Entities and the Subsidiaries are in compliance with the
terms and conditions of all such Licenses except as would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect.
(17) Financial Statements. The financial statements included in or incorporated by
reference into the Registration Statement and the Prospectus, together with the related financial
10
statement schedule and notes, present fairly (1) the financial position of the Company and its
consolidated Subsidiaries (and the combined financial position of any predecessor entities) at the
dates indicated; and (2) the results of operations, equity and cash flows of the Company and its
consolidated Subsidiaries (and the combined results of operations, stockholders’ equity, and cash
flows of any predecessor entities) for the periods specified; said financial statements have been
prepared from the books and records of the Company and its consolidated Subsidiaries (and any
predecessor entities) in conformity with U.S. generally accepted accounting principles
(“GAAP”) applied on a consistent basis throughout the periods involved. The related
financial statement schedule incorporated by reference into the Registration Statement and the
Prospectus, when considered in relation to the basic consolidated financial statements taken as a
whole, presents fairly, in all material respects, the information required to be stated therein.
All non- GAAP financial measures included in or incorporated by reference into the Registration
Statement and the Prospectus comply with the requirements of Regulation G and Item 10 of Regulation
S-K of the Securities Act Regulations to the extent such rules are applicable to such financial
statements. Other than the historical financial statements, and financial statement schedule
relating thereto included in or incorporated by reference into the Registration Statement and the
Prospectus, no other historical or pro forma financial statements (or schedules) are required by
the Securities Act or the Securities Act Regulations to be included therein or in any document
required to be filed with the Commission under the Exchange Act or the Exchange Act Regulations.
(18) Independent Registered Public Accounting Firm. The accountants who certified the
financial statements and supporting schedules included in or incorporated by reference into the
Registration Statement and delivered the Initial Comfort Letter referred to in Section 7(r)
hereof, are, and during the periods covered by such financial statements were, an independent
registered public accounting firm as required by the Securities Act, the Securities Act
Regulations, the Exchange Act, the Exchange Act Regulations, and the Public Company Accounting
Oversight Board (United States).
(19) REIT Status. Commencing with the taxable year ending December 31, 2004, the
Company has been and is organized and operated in conformity with the requirements for
qualification and taxation as a real estate investment trust (a “REIT”) under the Internal
Revenue Code 1986, as amended (the “Code”).
(20) Tax Returns and Matters. The Transaction Entities and each of the Subsidiaries
(including any predecessor entities) have filed all foreign, federal, state and local tax returns
that are required to be filed or have requested extensions thereof (except in any case in which the
failure so to file would not reasonably be expected to have a Material Adverse Effect) and have
paid all taxes required to be paid by them and any other assessment, fine or penalty levied against
them, to the extent that any of the foregoing is due and payable, except for any such assessment,
fine or penalty that (i) would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect or (ii) as described in or contemplated by the Prospectus.
Except as disclosed in the Prospectus, there is no pending or, to the knowledge of the Transaction
Entities, threatened special assessment, tax reduction proceeding or other action which could
increase or decrease the real property taxes or assessments of any Property, which would reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.
11
(21) No Other Offering Documents or Prospectuses. The Transaction Entities and each
of the Subsidiaries have not distributed, and prior to the completion of the distribution of the
Securities, will not distribute, any offering material in connection with the offering or sale of
the Securities to be sold hereunder by Xxxxx Fargo Securities, other than the Registration
Statement, the Prospectus, and any Permitted Free Writing Prospectus reviewed and consented to by
Xxxxx Fargo Securities.
(22) ERISA Matters.
(A) Each Transaction Entity is in compliance, in all material respects, with all
presently applicable provisions of the Employee Retirement Income Security Act of 1974, as
amended, including the regulations and published interpretations thereunder
(“ERISA”); no “reportable event” (as defined in ERISA other than an event for which
the notice requirements have been waived by regulations) has occurred with respect to any
“pension plan” (as defined in ERISA) for which any Transaction Entity would have any
liability; no Transaction Entity has incurred or expects to incur liability under (i) Title
IV of ERISA with respect to termination of, or withdrawal from, any “pension plan” or (ii)
Sections 412 or 4971 of the Code including the regulations and published interpretations
thereunder; and each “pension plan” for which any Transaction Entity would have any
liability that is intended to be qualified under Section 401(a) of the Code has received a
favorable determination letter from the Internal Revenue Service that such plan is so
qualified in all material respects and, except to the knowledge of the Transaction Entities,
nothing has occurred, whether by action or by failure to act, which would cause the loss of
such qualification, except where such non-compliance, reportable events, liabilities or
failure to be so qualified would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect.
(B) The assets of the Transactions Entities and the Subsidiaries do not constitute
“plan assets” of an ERISA regulated employee benefit plan.
(C) The Company is a “real estate operating company” as such term is defined in
paragraph (e) of the plan assets regulation in 29 C.F.R. Section 2510.3-101, or will be an
“operating company” as defined in the first sentence of paragraph (c) thereof.
(23) Property Matters.
(A) The Transaction Entities or the Subsidiaries have good and marketable title (either
in fee simple or pursuant to a leasehold interest) to all of the properties owned or leased
by them (the “Properties”), in each case, free and clear of all Liens except such as
(i) are disclosed in the Prospectus; or (ii) would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect. Any real property,
improvements, equipment and personal property held under lease by the Company or any
Subsidiary are held under valid, existing and enforceable leases which are in full force and
effect, and none of the Company, Operating Partnership nor any Subsidiary or, to any
Transaction Entity’s knowledge, any other party, is in default under any such lease, with
such exceptions as are disclosed in the Prospectus or would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect;
12
(B) All of the leases and subleases under which the Company, Operating Partnership or
any Subsidiary lease any portion of the Properties are in full force and effect; there are
no uncured events of default, or events that with the giving of notice or passage of time,
or both, would constitute an event of default, by any Transaction Entity nor any tenant
under any of the terms and provisions of the leases described above; and none of the
Company, Operating Partnership nor any Subsidiary has received any notice of any claim
asserted by anyone adverse to the rights of the Company, Operating Partnership or Subsidiary
under any of the leases or questioning or affecting the rights of the tenant of the
continued possession of the leased or subleased premises under any such lease or sublease,
in each case other than those that would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect or that have been, in the reasonable judgment of
the Company, adequately reserved for in the Company’s consolidated financial statements. No
tenant which has been specifically identified in the Prospectus under any of the leases at
the Properties has a right of first refusal or other right or option to purchase the
premises demised under such lease, other than those which are disclosed in the Prospectus or
with respect to properties the value of which are not material to the Transaction Entities
and the Subsidiaries as a whole;
(C) Except as disclosed in the Prospectus, none of the Transaction Entities, nor any
Subsidiary, knows of any violation of any municipal, state or federal law, rule or
regulation (including those pertaining to environmental matters) concerning the Properties
or any part thereof which would reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect;
(D) Each of the Properties complies with all applicable zoning laws, ordinances,
regulations, and deed restrictions or other covenants in all material respects and, if and
to the extent there is a failure to comply, such failure would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect;
(E) None of the Transaction Entities, nor any Subsidiary, has received from any
governmental authority any written notice of any condemnation of or zoning change affecting
the Properties or any part thereof, and none of the Transaction Entities nor any Subsidiary
or predecessor entity knows of any such condemnation or zoning change that is threatened
against any of the Properties and that, if consummated, would reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect;
(F) Each of the Properties is free of material structural defects and all building
systems contained therein are in good working order in all material respects, subject to
ordinary wear and tear, except as would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect, or, in each instance, the Company maintains
adequate reserves to effect reasonably required repairs, maintenance and capital
expenditures; and
(G) Water, stormwater, sanitary sewer, electricity and telephone service are all
available at the property lines of each Property over duly dedicated streets or perpetual
easements of record benefiting the applicable Property, except as would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.
13
(24) No Participating Interests. The mortgages and deeds of trust encumbering the
Properties and assets described in the Prospectus are not convertible, and neither the Transaction
Entities, any of the Subsidiaries, nor any person affiliated therewith holds a participating
interest therein, and such mortgages and deeds of trust are not cross-defaulted or
cross-collateralized to any property not owned directly or indirectly by the Transaction Entities
or any of the Subsidiaries.
(25) Insurance. The Operating Partnership and any Subsidiary that owns, or leases
under ground leases, real property has obtained title insurance on the fee interests (or leasehold
interests) in each of the Properties and other insurance covering such risks and in amounts that
are commercially reasonable for the assets owned by them, and in each case such title insurance and
other insurance is in full force and effect. Neither the Transaction Entities nor any of the
Subsidiaries has any reason to believe that any of them will not be able to obtain or renew its
existing insurance coverage as and when required by the preceding or as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its
business.
(26) Environmental Matters. Except as otherwise disclosed in the Prospectus or as
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect,
(A) none of the Transaction Entities, any of the Subsidiaries nor, to the best
knowledge of the Transaction Entities, any other owners of each Property at any time or any
other party has at any time handled, stored, treated, transported, manufactured, transferred
or otherwise dealt with, Hazardous Materials (as hereinafter defined) on, to or from the
Properties, other than by any such action taken in compliance with all applicable
Environmental Laws in all material respects;
(B) none of the Transaction Entities, any of the Subsidiaries nor, to the best
knowledge of the Transaction Entities, any other owners of each Property at any time or any
other party has at any time spilled, leaked, discharged, dumped, released, or otherwise
disposed of Hazardous Materials on, to or from the Properties, except where such events
would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect;
(C) the Transaction Entities do not intend to use the Properties or any subsequently
acquired properties, or to lease the Properties or any subsequently acquired properties to
any party that will use such Properties or any subsequently acquired properties, for the
purpose of handling, storing, treating, transporting, manufacturing, transferring or
otherwise dealing with Hazardous Materials other than by any such action taken in compliance
with all applicable Environmental Laws;
(D) the Transaction Entities do not intend to use the Properties or any subsequently
acquired properties, or to lease the Properties or any subsequently acquired properties to
any party that will use such Properties or any subsequently acquired properties, for the
purpose of spilling, leaking, releasing, discharging, dumping, or otherwise disposing of
Hazardous Materials on or from such Properties;
14
(E) none of the Transaction Entities nor any of the Subsidiaries knows of any seepage,
leak, discharge, release, emission, spill, or dumping of Hazardous Materials into soil or
waters (including, but not limited to, groundwater and surface water) on or adjacent to the
Properties or any other real property owned or occupied by any such party, or onto lands
from which Hazardous Materials might seep, flow or drain into such waters, except where such
events would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect;
(F) none of the Transaction Entities nor any of the Subsidiaries has received any
notice of or is aware of any receipt by any other party of a notice of, or has any knowledge
of any occurrence or circumstance that would give rise to a claim under or pursuant to any
Environmental Law, pertaining to Hazardous Materials on or originating from any of the
Properties or any assets described in the Prospectus (or, the most recent preliminary
prospectus) or any other real property owned or occupied by any such party or arising out of
the conduct of any such party, including without limitation a claim under or pursuant to any
Environmental Law (as hereinafter defined);
(G) none of the Transaction Entities nor any of the Subsidiaries has (A) been notified
that it is potentially liable under or (B) received any requests for information or other
correspondence concerning any site or facility under CERCLA or any similar law;
(H) none of the Properties are included or, to the best of the Transaction Entities’
knowledge, proposed for inclusion on the National Priorities List issued pursuant to CERCLA
(as hereinafter defined) by the United States Environmental Protection Agency (the
“EPA”) or, to the best of the Transaction Entities’ knowledge, proposed for
inclusion on any similar list or inventory issued pursuant to any other Environmental Law or
issued by any other Governmental Authority (as hereinafter defined);
(I) the Transaction Entities do not intend to use the Properties or other assets owned
by the Transaction Entities or the Subsidiaries other than in compliance with applicable
Environmental Laws;
(J) to the best knowledge of the Transaction Entities, the Properties contain no
above-ground and underground storage tanks, oil/water separators, sumps, or septic systems;
and
(K) (a) to the best knowledge of the Transaction Entities, no building or other
improvement located on the Properties contains any asbestos or asbestos-containing materials
that would reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect; (b) all asbestos or asbestos-containing materials are managed, handled,
treated, and removed in compliance with Environmental Law, except where such noncompliance
would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect; and (c) the Transaction Entities do not intend to manage, handle, treat, or
remove asbestos other than in compliance with Environmental Law.
15
As used herein, “Hazardous Material” means any chemical, substance, waste, material,
pollutant, contaminant, equipment or fixture defined as or deemed hazardous or toxic or otherwise
regulated under any Environmental Law, including, without limitation, RCRA hazardous wastes, CERCLA
hazardous substances, pesticides and other agricultural chemicals, oil and petroleum products or
byproducts and any constituents thereof, urea formaldehyde insulation, lead in paint or drinking
water, asbestos, and polychlorinated biphenyls (PCBs).
As used herein, “Environmental Laws” means all codes, laws (including, without
limitation, common law), ordinances, regulations, reporting or licensing requirements, rules, or
statutes in effect as of the Effective Date relating to pollution or protection of human health or
the environment (including ambient air, surface water, ground water, land surface, or subsurface
strata), including, without limitation (i) the Comprehensive Environmental Response Compensation
and Liability Act, 42 U.S.C. §§9601 et seq. (“CERCLA”); (ii) the Solid Waste Disposal Act,
as amended by the Resource Conservation and Recovery Act, 42 U.S.C. §§6901 et seq.,
(“RCRA”); (iii) the Emergency Planning and Community Right to Know Act (42 U.S.C. §§11001
et seq.); (iv) the Clean Air Act (42 U.S.C. §§ 7401 et seq.); (v) the Clean Water Act (33 U.S.C.
§§1251 et seq.); (vi) the Toxic Substances Control Act (15 U.S.C. §§2601 et seq.); (vii) the
Hazardous Materials Transportation Act (49 U.S.C. §§ 5101 et seq.); (viii) the Safe Drinking Water
Act (41 U.S.C. §§300f et seq.); (ix) any state, county, municipal or local statues, laws or
ordinances similar or analogous to the federal statutes listed in parts (i) through (viii),
inclusive, of this subparagraph, (x) any amendments to the statutes, laws or ordinances listed in
parts (i) through (ix), inclusive of this subparagraph, (xi) any rules, regulations, enforceable
guidelines or directives, orders or the like adopted pursuant to or implementing the statutes,
laws, ordinances and amendments listed in parts (i) through (x), inclusive, of this subparagraph;
and (xii) any other law, statute, ordinance, amendment, rule, regulation, guideline, directive,
order or the like relating to environmental, health or safety matters.
As used herein, a “Governmental Authority” means any federal, state, or local
governmental authority having or claiming jurisdiction over the properties and assets described in
the Prospectus.
(27) Independence of Environmental Consultants. None of the environmental consultants
that prepared the Phase I and II Environmental Audits with respect to any of the Properties was
employed for such purpose on a contingent basis or has any substantial interest (contingent or
otherwise) in the Transaction Entities or any of the Subsidiaries (including any predecessor
entity), and none of them nor any of their directors, officers or employees is connected with the
Transaction Entities or any of the Subsidiaries (or any of their predecessor entities) as a
promoter, selling agent, voting trustee, director, officer or employee.
(28) NYSE Listing Approval. The Securities have been approved for listing on the NYSE
subject to official notice of issuance.
(29) Labor Relations. With respect to employees of the Transaction Entities or any
Subsidiary, no labor dispute exists or, to the knowledge of the Transaction Entities, is imminent,
that would reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect.
16
(30) Intellectual Property Rights. The Transaction Entities and the Subsidiaries own,
possess or can acquire on reasonable terms, adequate trademarks, trade names and other rights to
inventions, know-how, patents, copyrights, confidential information and other intellectual property
(collectively, “Intellectual Property Rights”) necessary to conduct the business now
operated or presently intended to be operated by them, or presently employed by them, and have not
received any notice of infringement of or conflict with asserted rights of others with respect to
any Intellectual Property Rights that, if determined adversely to the Transaction Entities or any
of the Subsidiaries, would reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect.
(31) No Proceedings. There are no pending actions, suits or proceedings against or
affecting the Transaction Entities, any of the Subsidiaries or any of the Properties or other
assets that, if determined adversely to the Transaction Entities or any of the Subsidiaries, would
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, or
would materially and adversely affect the ability of the Transaction Entities to perform their
obligations under this Agreement; and no such actions, suits or proceedings are threatened or, to
the Transaction Entities’ knowledge, contemplated.
(32) No Material Adverse Change; No Material Transactions. Except as disclosed in the
Prospectus or the Registration Statement, since the respective dates as of which information is
given in the Prospectus and the Registration Statement, (1) there has been no Material Adverse
Effect, nor any development or event involving a prospective Material Adverse Effect; (2) there
have been no transactions entered into by the Company nor any of its Subsidiaries which are
material with respect to the Company and its Subsidiaries considered as one entity; or (3) except
for quarterly dividends on the Common Stock and the Series A Preferred Stock and related
distributions on OP Units and Series A units, respectively, that are consistent with past practice,
there has been no dividend or distribution of any kind declared, paid or made by the Company on any
class of its capital stock or by the Operating Partnership on any of its partnership interests.
(33) Investment Company Act Status. No Transaction Entity is and, after giving effect
to the offering and sale of the Securities and the application of the proceeds thereof as described
in the Prospectus, no Transaction Entity will be, an “investment company” as defined in the
Investment Company Act of 1940, as amended (the “Investment Company Act”).
(34) Adequate Disclosure of Contracts and Documents. There are no contracts or
documents which are required to be described in the Registration Statement or the Prospectus or the
documents incorporated by reference therein, or to be filed as exhibits thereto which have not been
so described and filed as required.
(35) Related Party Disclosures. No relationship, direct or indirect, exists between
or among any of the Transaction Entities on the one hand, and the directors, officers,
stockholders, customers or suppliers of the Transaction Entities on the other hand, which is
required to be described in the Prospectus and which is not so described.
(36) Books, Records, and Internal Controls. Each Transaction Entity (i) makes and
keeps books and records that are accurate in all material respects and (ii) maintains internal
accounting controls which provide reasonable assurance that (A) transactions are executed in
17
accordance with management’s authorization, (B) transactions are recorded as necessary to permit
preparation of its financial statements and to maintain accountability for its assets, (C) access
to its assets is permitted only in accordance with management’s authorization and (D) the reported
accountability for its assets is compared with existing assets at reasonable intervals.
(37) Actively Traded Security. The Common Stock is an “actively traded security”
excepted from the requirements of Rule 101 of Regulation M under the Exchange Act by subsection
(c)(1) of such rule.
(38) Stabilization Activities. None of the Transaction Entities nor any of their
respective officers, directors, members or controlling persons has taken, or will take, directly or
indirectly, any action designed to or that might reasonably be expected to result in a violation of
Regulation M under the Exchange Act or cause or result in stabilization or manipulation of the
price of any of the Company’s securities to facilitate the sale or resale of the Securities.
(39) Use of Proceeds. The Company intends to apply the net proceeds from the sale of
the Securities being sold by the Company in accordance with the description set forth in the
Prospectus under the heading “Use of Proceeds.”
(40) Subsidiary Tax Classification. Each of the Operating Partnership and any other
Subsidiary that is a partnership or a limited liability company has been properly classified either
as a partnership or as an entity disregarded as separate from the Company for federal income tax
purposes throughout the period from its formation through the date hereof.
(41) Adequate Disclosure of Acquisitions and Dispositions. There are no contracts,
letters of intent, term sheets, agreements, arrangements or understandings with respect to the
direct or indirect acquisition or disposition by the Company of interests in assets or real
property that is required to be described in the Prospectus that is not already so described.
(42) Internal Controls. The Company, the Operating Partnership and the Subsidiaries
have established and maintain “disclosure controls and procedures” (as such term is defined in Rule
13a-15 and 15d-15 promulgated under the Exchange Act); such disclosure controls and procedures are
designed to ensure that material information relating to the Company and its Subsidiaries, is made
known to the Company’s Chief Executive Officer and Chief Financial Officer by others within those
entities, and such disclosure controls and procedures are effective to perform the functions for
which they were established. The Company, the Operating Partnership and the Subsidiaries have
established and maintain internal control over financial reporting (as such term is defined in Rule
13a-15 and 15d-15 under the Exchange Act); such internal control over financial reporting is
designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted
accounting principles, including providing reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a
material effect on the financial statements. The Company’s independent registered public
accounting firm and the audit committee of the Board of Directors have been advised of: (i) any
significant deficiencies and material weaknesses in the design or operation of internal controls
which could adversely affect the Company’s ability to record, process, summarize, and report
financial data; and (ii) any fraud, whether or not
18
material, that involves management or other employees who have a role in the Company’s internal
controls. Since the date of the most recent evaluation of such disclosure controls and procedures,
there have been (I) no material weakness in the Company’s internal control over financial reporting
(whether or not remediated) and (II) no significant changes in internal controls or in other
factors that could significantly and negatively affect internal controls.
(43) Compliance with the Xxxxxxxx-Xxxxx Act. There is and has been no failure on the
part of the Company, the Operating Partnership and the Subsidiaries or any of such entities’
directors or officers, in their capacities as such, to comply in all material respects with any
provision of the Xxxxxxxx-Xxxxx Act, including Section 402 related to loans and Sections 302 and
906 related to certifications.
(44) Pending Proceedings and Examinations. The Registration Statement is not the
subject of a pending proceeding or examination under Section 8(d) or 8(e) of the Securities Act,
and the Company is not the subject of a pending proceeding under Section 8A of the Securities Act
in connection with the offering of the Securities.
(45) OFAC. Neither the Company nor any of the Subsidiaries, nor, to the knowledge of
the Company, any director, officer, agent, employee or affiliate of the Company or any of the
Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly
or indirectly use the proceeds of the offering of the Securities contemplated hereby, or lend,
contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or
other person or entity for the purpose of financing the activities of any person currently subject
to any U.S. sanctions administered by OFAC.
(46) Foreign Corrupt Practices Act. Neither the Company nor any of its Subsidiaries
nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other
person acting on behalf of the Company or any of its Subsidiaries is aware of or has taken any
action, directly or indirectly, that has resulted or would result in a violation by such persons of
the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder
(collectively, the “FCPA”), except for such violations which would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect, including, without
limitation, making use of the mails or any means or instrumentality of interstate commerce
corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of
any money, or other property, gift, promise to give, or authorization of the giving of anything of
value to any “foreign official” (as such term is defined in the FCPA) or any foreign political
party or official thereof or any candidate for foreign political office, in contravention of the
FCPA, and the Company and its Subsidiaries and, to the knowledge of the Company, its other
affiliates have conducted their businesses in compliance with the FCPA and have instituted and
maintain policies and procedures designed to ensure, and which are reasonably expected to continue
to ensure, continued compliance therewith.
(47) Money Laundering Laws. The operations of the Company and its Subsidiaries are
and have been conducted at all times in material compliance with applicable financial recordkeeping
and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all applicable jurisdictions, the rules
19
and regulations thereunder and any related or similar applicable rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, “Money
Laundering Laws”) and no action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with
respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.
(b) Certificates. Any certificate signed by any officer of the Company or the Operating
Partnership and delivered to Xxxxx Fargo Securities or to counsel for Xxxxx Fargo Securities shall
be deemed a representation and warranty by the Company or the Operating Partnership, as the case
may be, to Xxxxx Fargo Securities as to the matters covered thereby.
SECTION 6. Sale and Delivery to Xxxxx Fargo Securities; Settlement.
(a) Sale of Placement Securities. On the basis of the representations and warranties herein
contained and subject to the terms and conditions herein set forth, upon Xxxxx Fargo Securities’
acceptance of the terms of a Placement Notice, and unless the sale of the Placement Securities
described therein has been declined, suspended, or otherwise terminated in accordance with the
terms of this Agreement, Xxxxx Fargo Securities, for the period specified in the Placement Notice,
will use its commercially reasonable efforts consistent with its normal trading and sales practices
to sell such Placement Securities up to the amount specified, and otherwise in accordance with the
terms of such Placement Notice. Each of the Transaction Entities acknowledges and agrees that (i)
there can be no assurance that Xxxxx Fargo Securities will be successful in selling Placement
Securities, (ii) Xxxxx Fargo Securities will incur no liability or obligation to the Transaction
Entities or any other person or entity if it does not sell Placement Securities for any reason
other than a failure by Xxxxx Fargo Securities to use its commercially reasonable efforts
consistent with its normal trading and sales practices and applicable law and regulations to sell
such Placement Securities as required under this Agreement and (iii) Xxxxx Fargo Securities shall
be under no obligation to purchase Securities on a principal basis pursuant to this Agreement,
except as otherwise agreed by Xxxxx Fargo Securities and the Transaction Entities.
(b) Settlement of Placement Securities. Unless otherwise specified in the applicable
Placement Notice, settlement for sales of Placement Securities will occur on the third
(3rd) Trading Day (or such earlier day as is industry practice for regular-way trading)
following the date on which such sales are made (each, a “Settlement Date”). The amount of
proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement
Securities sold (the “Net Proceeds”) will be equal to the aggregate sales price received by
Xxxxx Fargo Securities at which such Placement Securities were sold, after deduction for (i) Xxxxx
Fargo Securities’ commission, discount or other compensation for such sales payable by the Company
pursuant to Section 2 hereof, and (ii) any transaction fees imposed by any governmental or
self-regulatory organization in respect of such sales.
(c) Delivery of Placement Securities. On or before each Settlement Date, the Company will, or
will cause its transfer agent to, electronically transfer the Placement Securities being sold by
crediting Xxxxx Fargo Securities’s or its designee’s account (provided Xxxxx Fargo Securities shall
have given the Company written notice of such designee prior to the Settlement Date) at The
Depository Trust Company through its Deposit and Withdrawal at Custodian
20
System or by such other means of delivery as may be mutually agreed upon by the parties hereto
which in all cases shall be freely tradable, transferable, registered shares in good deliverable
form. On each Settlement Date, Xxxxx Fargo Securities will deliver the related Net Proceeds in
same day funds to an account designated by the Company on, or prior to, the Settlement Date. The
Company agrees that if the Company, or its transfer agent (if applicable), defaults in its
obligation to deliver Placement Securities on a Settlement Date, the Company agrees that in
addition to and in no way limiting the rights and obligations set forth in Section 10(a) hereto, it
will (i) hold Xxxxx Fargo Securities harmless against any loss, claim, damage, or expense
(including reasonable legal fees and expenses), as incurred, arising out of or in connection with
such default by the Company or its transfer agent (if applicable) and (ii) pay to Xxxxx Fargo
Securities any commission, discount, or other compensation to which it would otherwise have been
entitled absent such default.
(d) Denominations; Registration. Certificates for the Securities, if any, shall be in such
denominations and registered in such names as Xxxxx Fargo Securities may request in writing at
least one full business day before the Settlement Date. The certificates for the Securities, if
any, will be made available for examination and packaging by Xxxxx Fargo Securities in The City of
New York not later than noon (New York time) on the business day prior to the Settlement Date.
(e) Limitations on Offering Size. Under no circumstances shall the Company cause or request
the offer or sale of any Securities if, after giving effect to the sale of such Securities, the
aggregate gross sales proceeds sold pursuant to this Agreement would exceed the lesser of (A)
together with all sales of Securities under this Agreement and the Alternative Distribution
Agreements, the Maximum Amount, (B) the amount available for offer and sale under the currently
effective Registration Statement and (C) the amount authorized from time to time to be issued and
sold under this Agreement by the Company’s board of directors, a duly authorized committee thereof
or a duly authorized executive committee, and notified to Xxxxx Fargo Securities in writing. Under
no circumstances shall the Company cause or request the offer or sale of any Securities at a price
lower than the minimum price authorized from time to time by the Company’s board of directors, duly
authorized committee thereof or a duly authorized executive committee, and notified to Xxxxx Fargo
Securities in writing. Further, under no circumstances shall the aggregate offering amount of
Securities sold pursuant to this Agreement and the Alternative Distribution Agreements, including
any separate underwriting or similar agreement covering principal transactions described in Section
1 of this Agreement and the Alternative Distribution Agreements, exceed the Maximum Amount.
(f) The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of
Securities shall only be effected by or through only one of Xxxxx Fargo Securities or the
Alternative Managers on any single given day, but in no event by more than one, and the Company
shall in no event request that Xxxxx Fargo Securities and any of the Alternative Managers sell
Securities on the same day; provided, however, that (a) the foregoing limitation shall not apply to
(i) exercise of any option, warrant, right or any conversion privilege set forth in the instrument
governing such security or (ii) sales solely to employees or security holders of the Company or its
Subsidiaries, or to a trustee or other person acquiring such securities for the accounts of such
persons, and (b) such limitation shall not apply on any day during which no sales are made pursuant
to this Agreement.
21
SECTION 7. Covenants of the Company and the Operating Partnership. Each of the
Transaction Entities covenants with Xxxxx Fargo Securities as follows:
(a) Registration Statement Amendments; Payment of Fees. After the date of this Agreement and
during any period in which a Prospectus relating to any Placement Securities is required to be
delivered by Xxxxx Fargo Securities under the Securities Act (including in circumstances where such
requirement may be satisfied pursuant to Rule 172 under the Securities Act), (i) the Company will
notify Xxxxx Fargo Securities promptly of the time when any subsequent amendment to the
Registration Statement, other than documents incorporated by reference, has been filed with the
Commission and/or has become effective or any subsequent supplement to the Prospectus has been
filed and of any comment letter from the Commission or any request by the Commission for any
amendment or supplement to the Registration Statement or Prospectus or for additional information;
(ii) the Company will not file any amendment or supplement to the Registration Statement or
Prospectus, other than documents incorporated by reference, relating to the Placement Securities or
a security convertible into the Placement Securities unless a copy thereof has been submitted to
Xxxxx Fargo Securities within a reasonable period of time before the filing and Xxxxx Fargo
Securities has not reasonably objected thereto (provided, however, that the failure of Xxxxx Fargo
Securities to make such objection shall not relieve the Company of any obligation or liability
hereunder, or affect Xxxxx Fargo Securities’ right to rely on the representations and warranties
made by the Company in this Agreement) and the Company will furnish to Xxxxx Fargo Securities at
the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by
reference into the Registration Statement or Prospectus, except for those documents available via
XXXXX; and (iii) the Company will cause each amendment or supplement to the Prospectus, other than
documents incorporated by reference, to be filed with the Commission as required pursuant to the
applicable paragraph of Rule 424(b) of the Securities Act (without reliance on Rule 424(b)(8) of
the Securities Act).
(b) Notice of Commission Stop Orders. The Company will advise Xxxxx Fargo Securities,
promptly after it receives notice or obtains knowledge thereof, of the issuance or threatened
issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement or of any other order preventing or suspending the use of the Prospectus or any Issuer
Free Writing Prospectus, or of the suspension of the qualification of the Placement Securities for
offering or sale in any jurisdiction or of the loss or suspension of any exemption from any such
qualification, or of the initiation or threatening of any proceedings for any of such purposes, or
of any examination pursuant to Section 8(e) of the Securities Act concerning the Registration
Statement or if the Company becomes the subject of a proceeding under Section 8A of the Securities
Act in connection with the offering of the Securities. The Company will make every reasonable
effort to prevent the issuance of any stop order, the suspension of any qualification of the
Securities for offering or sale and any loss or suspension of any exemption from any such
qualification, and if any such stop order is issued or any such suspension or loss occurs, to
obtain the lifting thereof at the earliest possible moment.
(c) Delivery of Registration Statement and Prospectus. The Company will furnish to Xxxxx
Fargo Securities and its counsel (at the expense of the Company) copies of the
22
Registration Statement, the Prospectus (including all documents incorporated by reference
therein) and all amendments and supplements to the Registration Statement or Prospectus, and any
Issuer Free Writing Prospectuses, that are filed with the Commission during any period in which a
Prospectus relating to the Placement Securities is required to be delivered under the Securities
Act (including all documents filed with the Commission during such period that are deemed to be
incorporated by reference therein), in each case as soon as reasonably practicable and in such
quantities and at such locations as Xxxxx Fargo Securities may from time to time reasonably
request. The copies of the Registration Statement and the Prospectus and any supplements or
amendments thereto furnished to Xxxxx Fargo Securities will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to XXXXX, except to the extent
permitted by Regulation S-T.
(d) Continued Compliance with Securities Laws. If at any time when a Prospectus is required
by the Securities Act or the Exchange Act to be delivered in connection with a pending sale of the
Placement Securities (including, without limitation, where such requirement may be satisfied
pursuant to Rule 172), any event shall occur or condition shall exist as a result of which it is
necessary, in the opinion of counsel for Xxxxx Fargo Securities or for the Company, to amend the
Registration Statement or amend or supplement the Prospectus in order that the Prospectus will not
include any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein not misleading in the light of the circumstances existing at the
time it is delivered to a purchaser, or if it shall be necessary, in the opinion of such counsel,
at any such time to amend the Registration Statement or amend or supplement the Prospectus in order
to comply with the requirements of the Securities Act, the Company will promptly notify Xxxxx Fargo
Securities to suspend the offering of Placement Securities during such period and the Company will
promptly prepare and file with the Commission such amendment or supplement as may be necessary to
correct such statement or omission or to make the Registration Statement or the Prospectus comply
with such requirements, and the Company will furnish to Xxxxx Fargo Securities such number of
copies of such amendment or supplement as Xxxxx Fargo Securities may reasonably request. If at any
time following the issuance of an Issuer Free Writing Prospectus there occurred or occurs an event
or development as a result of which such Issuer Free Writing Prospectus conflicted, conflicts or
would conflict with the information contained in the Registration Statement or the Prospectus or
included, includes or would include an untrue statement of a material fact or omitted, omits or
would omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances, prevailing at that subsequent time, not misleading, the Company will promptly
notify Xxxxx Fargo Securities to suspend the offering of Placement Securities during such period
and the Company will, subject to Section 7(a) hereof, promptly amend or supplement such Issuer Free
Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.
(e) Blue Sky and Other Qualifications. The Company will use its best efforts, in cooperation
with Xxxxx Fargo Securities, to qualify the Placement Securities for offering and sale, or to
obtain an exemption for the Securities to be offered and sold, under the applicable securities laws
of such states and other jurisdictions (domestic or foreign) as Xxxxx Fargo Securities may
designate and to maintain such qualifications and exemptions in effect for so long as required for
the distribution of the Securities (but in no event for less than one year from the date of this
Agreement); provided, however, that the Company shall not be obligated to file any general consent
to service of process or to qualify as a foreign corporation or as a dealer in
23
securities in any jurisdiction in which it is not so qualified or to subject itself to
taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.
In each jurisdiction in which the Placement Securities have been so qualified or exempt, the
Company will file such statements and reports as may be required by the laws of such jurisdiction
to continue such qualification or exemption, as the case may be, in effect for so long as required
for the distribution of the Placement Securities (but in no event for less than one year from the
date of this Agreement).
(f) Rule 158. The Company will timely file such reports pursuant to the Exchange Act as are
necessary in order to make generally available to its securityholders as soon as practicable an
earnings statement that will satisfy the provisions of Section 11(a) of the Securities Act.
(g) Use of Proceeds. The Company will use the net proceeds received by it from the sale of
the Securities in the manner specified in the Prospectus under “Use of Proceeds.”
(h) Listing. During any period in which the Prospectus relating to the Placement Securities
is required to be delivered by Xxxxx Fargo Securities under the Securities Act with respect to a
pending sale of the Placement Securities (including in circumstances where such requirement may be
satisfied pursuant to Rule 172 under the Securities Act), the Company will use its commercially
reasonable efforts to cause the Placement Securities to be listed on the NYSE.
(i) Filings with the NYSE. The Company will timely file with the NYSE all material documents
and notices required by the NYSE of companies that have or will issue securities that are traded on
the NYSE.
(j) Reporting Requirements. The Company, during any period when the Prospectus is required to
be delivered under the Securities Act and the Exchange Act (including in circumstances where such
requirement may be satisfied pursuant to Rule 172 under the Securities Act), will (1) comply with
all provisions of the Act and the Securities Act Regulations and the Exchange Act and Exchange Act
Regulations and (2) file all documents required to be filed with the Commission pursuant to the
Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.
(k) Notice of Other Sales. During the pendency of any Placement Notice given hereunder, the
Company shall provide Xxxxx Fargo Securities prior notice at least three (3) business days before
it offers to sell, contracts to sell, sells, grants any option to sell or otherwise disposes of any
shares of Common Stock (other than Placement Securities offered pursuant to the provisions of this
Agreement or the Alternative Distribution Agreements) or securities convertible into or
exchangeable for Common Stock, warrants or any rights to purchase or acquire Common Stock;
provided, that such notice shall not be required in connection with the (i) issuance, grant or sale
of Common Stock, options to purchase Common Stock or Common Stock issuable upon the exercise of
options or other equity awards pursuant to any stock option, stock bonus or other stock or
compensatory plan or arrangement described in the Prospectus, including Common Stock issuable upon
redemption of OP Units of the Operating Partnership or upon exchange or redemption of the
Exchangeable Notes, (ii) the issuance of securities in
24
connection with an acquisition, merger or sale or purchase of assets described in the
Prospectus, or (iii) the issuance or sale of Common Stock pursuant to any dividend reinvestment
plan that the Company may adopt from time to time, provided the implementation of such plan is
disclosed to Xxxxx Fargo Securities in advance.
(l) Change of Circumstances. The Company will, at any time during a fiscal quarter in which
the Company intends to tender a Placement Notice or sell Placement Securities, advise Xxxxx Fargo
Securities promptly after it shall have received notice or obtained knowledge thereof, of any
information or fact that would alter or affect in any material respect any opinion, certificate,
letter or other document provided to Xxxxx Fargo Securities pursuant to Section 7 of this
Agreement.
(m) Due Diligence Cooperation. The Company will cooperate with any reasonable due diligence
review conducted by Xxxxx Fargo Securities or its agents in connection with the transactions
contemplated hereby, including, without limitation, providing information and making available
documents and senior officers, during regular business hours and at the Company’s principal
offices, as Xxxxx Fargo Securities may reasonably request after consultation with the Company.
(n) Disclosure of Sales. The Company will disclose in its quarterly reports on Form 10-Q and
in its annual report on Form 10-K the number of Placement Securities sold through Xxxxx Fargo
Securities during the relevant quarter.
(o) Representation Dates; Certificate. On or prior to the date that the first Securities are
sold pursuant to the terms of this Agreement and (1) each time the Company:
(i) files the Prospectus relating to the Securities or amends or supplements (other
than a prospectus supplement relating solely to an offering of securities other than the
Securities) the Registration Statement or the Prospectus relating to the Securities by means
of a post-effective amendment, sticker, or supplement but not by means of incorporation of
documents by reference into the Registration Statement or the Prospectus relating to the
Securities;
(ii) files an annual report on Form 10-K under the Exchange Act;
(iii) files its quarterly reports on Form 10-Q under the Exchange Act; or
(iv) files a report on Form 8-K containing amended financial information (other than an
earnings release, to “furnish” information pursuant to Items 2.02 or 7.01 of Form 8-K or to
provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassifications of
certain properties as discontinued operations in accordance with Statement of Financial
Accounting Standards No. 144) under the Exchange Act, or
(2) at any other time reasonably requested by Xxxxx Fargo Securities (each date of filing of
one or more of the documents referred to in clause (1) and any time of request pursuant to
clause (2) shall be a “Representation Date”);
25
the Company shall furnish Xxxxx Fargo Securities with a certificate, in the form attached
hereto as Exhibit F within three (3) Trading Days of any Representation Date. The
requirement to provide a certificate under this Section 7(o) shall be waived for any Representation
Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until
the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such
calendar quarter shall be considered a Representation Date) and the next occurring Representation
Date; provided, however, that such waiver shall not apply for any Representation Date on which the
Company files its annual report on Form 10-K. Notwithstanding the foregoing, if the Company
subsequently decides to sell Placement Securities following a Representation Date when the Company
relied on such waiver and did not provide Xxxxx Fargo Securities with a certificate under this
Section 7(o), then before the Company delivers the Placement Notice or Xxxxx Fargo Securities sells
any Placement Securities, the Company shall provide Xxxxx Fargo Securities with a certificate, in
the form attached hereto as Exhibit F, dated the date of the Placement Notice.
(p) Company Counsel Legal Opinions. (i) On or prior to the date that the first Securities are
sold pursuant to the terms of this Agreement and (ii) within three (3) Trading Days of each
Representation Date with respect to which the Company is obligated to deliver a certificate in the
form attached hereto as Exhibit F for which no waiver is applicable, the Company shall
cause to be furnished to Xxxxx Fargo Securities written opinions of Xxxxxx & Xxxxxxx LLP and
Xxxxxxx LLP (collectively, “Company Counsel”), or other counsel satisfactory to Xxxxx Fargo
Securities, in form and substance reasonably satisfactory to Xxxxx Fargo Securities and its
counsel, dated the date that the opinion is required to be delivered, substantially similar to the
forms attached hereto as Exhibit E-1, Exhibit E-2 and Exhibit E-3,
modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended
or supplemented; provided, however, that in lieu of such opinions for subsequent Representation
Dates, any such counsel may furnish Xxxxx Fargo Securities with a letter (a “Reliance
Letter”) to the effect that Xxxxx Fargo Securities may rely on a prior opinion delivered under
this Section 7(p) to the same extent as if it were dated the date of such letter (except that
statements in such prior opinion shall be deemed to relate to the Registration Statement and the
Prospectus as amended or supplemented at such Representation Date). In rendering such opinions,
such counsel may rely, as to matters of fact (but not as to legal conclusions), to the extent they
deem proper, on certificates of responsible officers of the Transaction Entities and public
officials. In addition, Xxxxxx & Xxxxxxx LLP, in rendering such opinion, may rely on and assume
the accuracy of an opinion of Xxxxxxx LLP with respect to certain matters of Maryland law.
(q) Agent Counsel Legal Opinion. On or prior to the date that the first Securities are sold
pursuant to the terms of this Agreement, within three (3) Trading Days of each Representation Date
with respect to which the Company is obligated to deliver a certificate in the form attached hereto
as Exhibit F for which no waiver is applicable, Xxxxx Fargo Securities shall have received
the favorable opinion of DLA Piper LLP (US), counsel to Xxxxx Fargo Securities, dated as of such
date, in customary form and substance satisfactory to Xxxxx Fargo Securities, and the Company shall
have furnished to such counsel such documents as they reasonably request for the purpose of
enabling them to pass upon such matters. In rendering such opinion, DLA Piper LLP (US) may rely as
to the organization and incorporation of the Transaction Entities and other matters governed by
Maryland law upon the opinion of Xxxxxxx LLP referred to above.
26
(r) Comfort Letter. On or prior to the date that the first Securities are sold pursuant to
the terms of this Agreement, within three (3) Trading Days of each Representation Date with respect
to which the Company is obligated to deliver a certificate in the form attached hereto as
Exhibit F for which no waiver is applicable, the Company shall cause its independent
accountants (and any other independent accountants whose report is included in the Registration
Statement or the Prospectus) to furnish Xxxxx Fargo Securities letters (the “Comfort
Letters”), dated the date the Comfort Letter is delivered, in form and substance satisfactory
to Xxxxx Fargo Securities, (i) confirming that they are an independent registered public accounting
firm within the meaning of the Securities Act, the Exchange Act and the PCAOB, (ii) stating, as of
such date, the conclusions and findings of such firm with respect to the financial information and
other matters ordinarily covered by accountants’ “comfort letters” to underwriters in connection
with registered public offerings (the first such letter, the “Initial Comfort Letter”) and
(iii) updating the Initial Comfort Letter with any information that would have been included in the
Initial Comfort Letter had it been given on such date and modified as necessary to relate to the
Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.
(s) Market Activities. Neither the Company nor the Operating Partnership will, directly or
indirectly, (i) take any action designed to cause or result in, or that constitutes or might
reasonably be expected to constitute, the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Securities or (ii) sell, bid for,
or purchase the Securities to be issued and sold pursuant to this Agreement, or pay anyone any
compensation for soliciting purchases of the Securities to be issued and sold pursuant to this
Agreement other than Xxxxx Fargo Securities; provided, however, that the Company may bid for and
purchase its Common Stock in accordance with Rule 10b-18 under the Exchange Act.
(t) Investment Company Act. The Company will conduct its affairs in such a manner so as to
reasonably ensure that neither it nor any of its Subsidiaries will be or become, at any time prior
to the termination of this Agreement, an “investment company,” as such term is defined in the
Investment Company Act, assuming no change in the Commission’s current interpretation as to
entities that are not considered an investment company.
(u) Regulation M. If the Company has reason to believe that the exemptive provisions set
forth in Rule 101(c)(1) of Regulation M under the Exchange Act are not satisfied with respect to
the Company or the Common Stock, it shall promptly notify Xxxxx Fargo Securities and sales of the
Placement Securities under this Agreement shall be suspended until that or other exemptive
provisions have been satisfied in the judgment of each party.
(v) REIT Treatment. The Company will use its best efforts to maintain its qualification as a
REIT under the Code.
SECTION 8. Payment of Expenses.
(a) Expenses. The Company will pay all expenses incident to the performance of its
obligations under this Agreement, including (i) the preparation, printing and filing of the
Registration Statement (including financial statements and exhibits) as originally filed and of
each amendment and supplement thereto, (ii) the printing and delivery to Xxxxx Fargo Securities
27
of this Agreement and such other documents as may be required in connection with the offering,
purchase, sale, issuance or delivery of the Placement Securities, (iii) the preparation, issuance
and delivery of the certificates, if any, for the Placement Securities to Xxxxx Fargo Securities,
including any stock or other transfer taxes and any capital duties, stamp duties or other duties or
taxes payable upon the sale, issuance or delivery of the Placement Securities to Xxxxx Fargo
Securities, (iv) the fees and disbursements of the counsel, accountants and other advisors to the
Company, (v) the qualification or exemption of the Placement Securities under state securities laws
in accordance with the provisions of Section 7(e) hereof, including filing fees and the reasonable
fees and disbursements of counsel for Xxxxx Fargo Securities in connection therewith and in
connection with the preparation of a state securities law or “blue sky” survey and any supplements
thereto, (vi) the printing and delivery to Xxxxx Fargo Securities of copies of any permitted Free
Writing Prospectus and the Prospectus and any amendments or supplements thereto, (vii) the
preparation, printing and delivery to Xxxxx Fargo Securities of copies of the blue sky survey and
any Canadian “wrapper” and any supplements thereto, (viii) the fees and expenses of the transfer
agent and registrar for the Securities, (ix) the filing fees incident to any review by FINRA of the
terms of the sale of the Securities, (x) the fees and expenses incurred in connection with the
listing of the Placement Securities on the NYSE, and (xi) the Company shall reimburse Xxxxx Fargo
Securities, UBS Securities and Xxxxxxx Xxxxx (the “Managers”) for their
reasonable out-of-pocket fees and disbursements of counsel for the Managers incurred in connection
with this Agreement and the Alternative Distribution Agreements in an amount equal to the product
of (a) a fraction equal to (i) the aggregate offering amount remaining unsold under this Agreement
and the Alternative Distribution Agreements on the date which is six months after the date of this
Agreement (or such earlier date at which the Company terminates the Agreement) (the
“Determination Date”) divided by (ii) the aggregate offering amount authorized to be sold
pursuant to this Agreement and the Alternative Distribution Agreements, and (b) the aggregate
reasonable out-of-pocket fees and disbursements of counsel for the Managers incurred by the
Managers in connection with the transactions contemplated by this Agreement and the Alternative
Distribution Agreement to and including the Determination Date (the “Expenses”); provided,
however, that the Company shall not be obligated pursuant to this
Section 8(a)(xi) to reimburse the
Managers for any Expenses in excess of $150,000 in the aggregate. The Expenses calculated pursuant
to the preceding sentence shall be divided among the Managers in amounts proportionate to the
aggregate offering amount sold by each Manager under this Agreement and the Alternative
Distribution Agreements, after taking into account the amount of Expenses actually paid by each
Manager, and shall be due and payable by the Company to the Managers within 5 business days of the
Determination Date.
(b) Termination of Agreement. If this Agreement is terminated by Xxxxx Fargo Securities in
accordance with the provisions of Section 9 or Section 13(a)(i) hereof, the Company shall reimburse
Xxxxx Fargo Securities for all of their out-of-pocket expenses, including the reasonable fees and
disbursements of counsel for Xxxxx Fargo Securities (to be calculated in accordance with
Section 8(a)(xi)).
SECTION 9. Conditions of Xxxxx Fargo Securities’ Obligations. The obligations of
Xxxxx Fargo Securities hereunder with respect to a Placement will be subject to the continuing
accuracy and completeness of the representations and warranties of the Company and the Operating
Partnership contained in this Agreement or in certificates of any officer of the Company, the
Operating Partnership or any Subsidiary of the Company delivered pursuant to the
28
provisions hereof, to the performance by the Company of its covenants and other obligations
hereunder, and to the following further conditions:
(a) Effectiveness of Registration Statement. The Registration Statement shall have
become effective and shall be available for (i) all sales of Placement Securities issued
pursuant to all prior Placement Notices and (ii) the sale of all Placement Securities
contemplated to be issued by any Placement Notice.
(b) No Material Notices. None of the following events shall have occurred and be
continuing: (i) receipt by the Company or any of its Subsidiaries of any request for
additional information from the Commission or any other federal or state governmental
authority during the period of effectiveness of the Registration Statement, the response to
which would require any post-effective amendments or supplements to the Registration
Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or
state governmental authority of any stop order suspending the effectiveness of the
Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt
by the Company of any notification with respect to the suspension of the qualification or
exemption from qualification of any of the Placement Securities for sale in any jurisdiction
or the initiation or threatening of any proceeding for such purpose; (iv) the occurrence of
any event that makes any material statement made in the Registration Statement or the
Prospectus, or any Issuer Free Writing Prospectus, or any material document incorporated or
deemed to be incorporated therein by reference untrue in any material respect or that
requires the making of any changes in the Registration Statement, related Prospectus, or any
Issuer Free Writing Prospectus, or such documents so that, in the case of the Registration
Statement, it will not contain any materially untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements
therein not misleading and, that in the case of the Prospectus and any Issuer Free Writing
Prospectus, it will not contain any materially untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.
(c) Material Changes. Except as contemplated in the Prospectus, or disclosed in the
Company’s reports filed with the Commission, there shall not have been any change in the
condition, financial or otherwise, or in the business, properties, earnings, results of
operations or prospects of the Company except as would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect.
(d) Opinion of Counsel for Company. Xxxxx Fargo Securities shall have received the
favorable opinion of Company Counsel, required to be delivered pursuant to Section 7(p) on
or before the date on which such delivery of such opinion is required pursuant to Section
7(p).
(e) Representation Certificate. Xxxxx Fargo Securities shall have received the
certificate required to be delivered pursuant to Section 7(o) on or before the date on which
delivery of such certificate is required pursuant to Section 7(o).
29
(f) Accountant’s Comfort Letter. Xxxxx Fargo Securities shall have received the
Comfort Letter required to be delivered pursuant to Section 7(r) on or before the date on
which such delivery of such Comfort Letter is required pursuant to Section 7(r).
(g) Approval for Listing. The Placement Securities shall either have been (i) approved
for listing on NYSE, subject only to notice of issuance, or (ii) the Company shall have
filed an application for listing of the Placement Securities on NYSE at, or prior to, the
issuance of any Placement Notice.
(h) No Suspension. Trading in the Securities shall not have been suspended on the
NYSE.
(i) Additional Documents. On each date on which the Company is required to deliver a
certificate pursuant to Section 7(o), counsel for Xxxxx Fargo Securities shall have been
furnished with such documents and opinions as they may reasonably require for the purpose of
enabling them to pass upon the issuance and sale of the Securities as herein contemplated,
or in order to evidence the accuracy of any of the representations or warranties, or the
fulfillment of any of the conditions, contained in this Agreement.
(j) Securities Act Filings Made. All filings with the Commission required by Rule 424
under the Securities Act to have been filed prior to the issuance of any Placement Notice
hereunder shall have been made within the applicable time period prescribed for such filing
by Rule 424.
(k) Termination of Agreement. If any condition specified in this Section 9 shall not
have been fulfilled when and as required to be fulfilled, this Agreement may be terminated
by Xxxxx Fargo Securities by notice to the Company. Notice of such cancellation shall be
given in writing and addressed to each of the individuals of the Company set forth on
Exhibit B.
SECTION 10. Indemnification.
(a) Indemnification by the Transaction Entities. The Transaction Entities, jointly and
severally, agree to indemnify and hold harmless Xxxxx Fargo Securities, its partners, members,
directors, officers, employees and agents and each person, if any, who controls Xxxxx Fargo
Securities within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act
as follows:
(i) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, joint or several, arising out of or based upon any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement (or any
amendment thereto), or the omission or alleged omission therefrom of a material fact
required to be stated therein or necessary to make the statements therein not misleading, or
arising out of any untrue statement or alleged untrue statement of a material fact included
in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or
supplement thereto), or the omission or alleged omission therefrom of a material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading;
30
(ii) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, joint or several, to the extent of the aggregate amount paid in settlement of any
litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or of any claim whatsoever based upon any such untrue statement or omission,
or any such alleged untrue statement or omission; provided that (subject to Section 10(d)
below) any such settlement is effected with the written consent of the Transaction Entities;
and
(iii) against any and all expense whatsoever, as incurred (including the fees and
disbursements of counsel), reasonably incurred in investigating, preparing or defending
against any litigation, or any investigation or proceeding by any governmental agency or
body, commenced or threatened, or any claim whatsoever based upon any such untrue statement
or omission, or any such alleged untrue statement or omission, to the extent that any such
expense is not paid under (i) or (ii) above,
provided, however, that this indemnity agreement shall not apply to any loss,
liability, claim, damage or expense to the extent arising out of any untrue statement or omission
or alleged untrue statement or omission made in reliance upon and in conformity with written
information furnished to the Company by Xxxxx Fargo Securities expressly for use in the
Registration Statement (or any amendment thereto), or in any related Issuer Free Writing Prospectus
or the Prospectus (or any amendment or supplement thereto).
(b) Indemnification by Xxxxx Fargo Securities. Xxxxx Fargo Securities agrees to indemnify and
hold harmless each Transaction Entity, each of its directors, each of its officers who signed the
Registration Statement, and each person, if any, who controls the Transaction Entities within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all
loss, liability, claim, damage and expense described in the indemnity contained in subsection (a)
of this Section 10, as incurred, but only with respect to untrue statements or omissions, or
alleged untrue statements or omissions, made in the Registration Statement (or any amendment
thereto), any Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with written information furnished to the Company by
Xxxxx Fargo Securities expressly for use therein.
(c) Actions against Parties; Notification. Each indemnified party shall give notice as
promptly as reasonably practicable to each indemnifying party of any action commenced against it in
respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party
shall not relieve such indemnifying party from any liability hereunder to the extent it is not
materially prejudiced as a result thereof and in any event shall not relieve it from any liability
which it may have otherwise than on account of this indemnity agreement. In case any such action
is brought against any indemnified party and it notifies the indemnifying party of the commencement
thereof, the indemnifying party will be entitled to participate therein and, to the extent that it
may wish, jointly with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel satisfactory to such indemnified party (who shall not, except with the
consent of the indemnified party, be counsel to the indemnifying party), and after notice from the
indemnifying party to such indemnified party of its election so to assume the defense thereof, the
indemnifying party will not be liable to such indemnified party under this Section for any legal or
other expenses subsequently incurred by such indemnified party in
31
connection with the defense thereof other than reasonable costs of investigation. In no event
shall the indemnifying parties be liable for the fees and expenses of more than one counsel (in
addition to any local counsel) separate from their own counsel for Xxxxx Fargo Securities and the
Alternative Managers and each person, if any, who controls Xxxxx Fargo Securities or the
Alternative Managers within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act, and the fees and expenses of more than one counsel (in addition to any local counsel)
separate from their own counsel for the Transaction Entities, their directors, each of the
Company’s officers who signed the Registration Statement and each person, if any, who controls the
Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act,
in each case in connection with any one action or separate but similar or related actions in the
same jurisdiction arising out of the same general allegations or circumstances. No indemnifying
party shall, without the prior written consent of the indemnified parties, settle or compromise or
consent to the entry of any judgment with respect to any litigation, or any investigation or
proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in
respect of which indemnification or contribution could be sought under this Section 10 or
Section 11 hereof (whether or not the indemnified parties are actual or potential parties thereto),
unless such settlement, compromise or consent (i) includes an unconditional release of each
indemnified party from all liability arising out of such litigation, investigation, proceeding or
claim and (ii) does not include a statement as to or an admission of fault, culpability or a
failure to act by or on behalf of any indemnified party.
(d) Settlement Without Consent if Failure to Reimburse. If at any time an indemnifying party
shall not have assumed the defense of an action in accordance with Section 10(c), or if an
indemnified party shall have incurred reasonable fees and expenses of counsel prior to an
indemnifying party assuming the defense of an action in accordance with Section 10(c), and an
indemnified party shall have requested an indemnifying party to reimburse the indemnified party for
reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for
any settlement of the nature contemplated by Section 10(a)(ii) effected without its written consent
if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party
of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of
such settlement at least 30 days prior to such settlement being entered into and (iii) such
indemnifying party shall not have reimbursed such indemnified party in accordance with such request
prior to the date of such settlement.
SECTION 11. Contribution. If the indemnification provided for in Section 10 hereof is
for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of
any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate
to reflect the relative benefits received by the Transaction Entities on the one hand and Xxxxx
Fargo Securities on the other hand from the offering of the Securities pursuant to this Agreement
or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)
above but also the relative fault of the Transaction Entities on the one hand and of Xxxxx Fargo
Securities on the other hand in connection with the statements or omissions that resulted in such
losses, liabilities, claims, damages or expenses.
32
The relative benefits received by the Transaction Entities on the one hand and Xxxxx Fargo
Securities on the other hand in connection with the offering of the Securities pursuant to this
Agreement shall be deemed to be in the same respective proportions as the total net proceeds from
the offering of the Securities pursuant to this Agreement (before deducting expenses) received by
the Transaction Entities bear to the total discount, commissions or other compensation received by
Xxxxx Fargo Securities.
The relative fault of the Transaction Entities on the one hand and Xxxxx Fargo Securities on
the other hand shall be determined by reference to, among other things, whether any such untrue or
alleged untrue statement of a material fact or omission or alleged omission to state a material
fact relates to information supplied by the Transaction Entities or by Xxxxx Fargo Securities and
the parties’ relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission.
The Transaction Entities and Xxxxx Fargo Securities agree that it would not be just and
equitable if contribution pursuant to this Section 11 were determined by pro rata allocation or by
any other method of allocation which does not take account of the equitable considerations referred
to above in this Section 11. The aggregate amount of losses, liabilities, claims, damages and
expenses incurred by an indemnified party and referred to above in this Section 11 shall be deemed
to include any legal or other expenses reasonably incurred by such indemnified party in
investigating, preparing or defending against any litigation, or any investigation or proceeding by
any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any
such untrue or alleged untrue statement or omission or alleged omission.
Notwithstanding the provisions of this Section 11, Xxxxx Fargo Securities shall not be
required to contribute any amount in excess of the discount, commission or other compensation
received by Xxxxx Fargo Securities hereunder.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.
For purposes of this Section 11, each person, if any, who controls Xxxxx Fargo Securities
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have
the same rights to contribution as Xxxxx Fargo Securities, and each director of the Transaction
Entities, each officer of the Company who signed the Registration Statement, and each person, if
any, who controls the Transaction Entities within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act shall have the same rights to contribution as the Transaction
Entities.
SECTION 12. Representations, Warranties and Agreements to Survive Delivery. All
representations, warranties and agreements contained in this Agreement or in certificates of
officers of the Transaction Entities or any of its Subsidiaries submitted pursuant hereto, shall
remain operative and in full force and effect, regardless of any investigation made by or on behalf
of Xxxxx Fargo Securities or controlling person, or by or on behalf of the Transaction Entities,
and shall survive delivery of the Securities to Xxxxx Fargo Securities.
33
SECTION 13. Termination of Agreement.
(a) Termination; General. Xxxxx Fargo Securities may terminate this Agreement, by notice to
the Company, as hereinafter specified at any time (i) if there has been, since the time of
execution of this Agreement or since the date as of which information is given in the Prospectus,
any change, or any development or event involving a prospective change, in the condition, financial
or otherwise, or in the business, properties, earnings, results of operations or prospects of the
Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary
course of business, which individually or in the aggregate, in the sole judgment of Xxxxx Fargo
Securities is material and adverse and makes it impractical or inadvisable to market the Securities
or to enforce contracts for the sale of the Securities, (ii) if there has occurred any material
adverse change in the financial markets in the United States or the international financial
markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any
change or development involving a prospective change in national or international political,
financial or economic conditions, in each case the effect of which is such as to make it, in the
judgment of Xxxxx Fargo Securities, impracticable or inadvisable to market the Securities or to
enforce contracts for the sale of the Securities, (iii) if trading in the Placement Securities has
been suspended or limited by the Commission or the NYSE, or if trading generally on the NYSE has
been suspended or limited, or minimum prices for trading have been fixed on the NYSE, (iv) if any
suspension of trading of any securities of the Company on any exchange or in the over-the-counter
market shall have occurred and be continuing, (v) if a major disruption of securities settlements
or clearance services in the United States shall have occurred and be continuing, or (vi) if a
banking moratorium has been declared by either U.S. Federal or New York authorities.
(b) Termination by the Transaction Entities. The Transaction Entities shall have the right,
by giving ten (10) days notice as hereinafter specified to terminate this Agreement in their sole
discretion at any time after the date of this Agreement.
(c) Termination by Xxxxx Fargo Securities. Xxxxx Fargo Securities shall have the right, by
giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole
discretion at any time after the date of this Agreement.
(d) Automatic Termination. Unless earlier terminated pursuant to this Section 13, this
Agreement shall automatically terminate upon the issuance and sale of the Maximum Amount of
Securities through Xxxxx Fargo Securities and the Alternative Managers pursuant to this Agreement
and the Alternative Distribution Agreements.
(e) Continued Force and Effect. This Agreement shall remain in full force and effect unless
terminated pursuant to Sections 9(k), 13(a), (b), (c), or (d) above or otherwise by mutual
agreement of the parties.
(f) Effectiveness of Termination. Any termination of this Agreement shall be effective on the
date specified in such notice of termination; provided, however, that such termination shall not be
effective until the close of business on the date specified in such notice by Xxxxx Fargo
Securities or the Transaction Entities, as the case may be. If such termination shall occur prior
to the Settlement Date for any sale of Placement Securities, such Placement Securities shall settle
in accordance with the provisions of this Agreement.
34
(g) Liabilities. If this Agreement is terminated pursuant to Section 9(k) or this
Section 13, such termination shall be without liability of any party to any other party except as
provided in Section 8 hereof, and except that,
in the case of any termination of this Agreement, Section 5, Section 10, Section 11, Section 12,
and Section 21 hereof shall survive such termination and remain in full force and effect.
SECTION 14. Notices. Except as otherwise provided in this Agreement, all notices and
other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted by any standard form of telecommunication. Notices to Xxxxx Fargo Securities
shall be directed to Xxxxx Fargo Securities at Xxxxx Fargo Securities, LLC, 000 Xxxx Xxxxxx, Xxx
Xxxx, Xxx Xxxx 00000, fax no. 000-000-0000, Attention of Xxxxxxx X. Xxxxxx; notices to the
Transaction Entities shall be directed to them at BioMed Realty Trust, Inc., 00000 Xxxxxxxx Xxxxxx
Xxxxx, Xxx Xxxxx, Xxxxxxxxxx 00000, fax no. 000-000-0000, Attention: General Counsel/Corporate
Legal, with a copy to Xxxxxx & Xxxxxxx LLP, 00000 Xxxx Xxxxx Xxxxx, Xxxxx 000, Xxx Xxxxx,
Xxxxxxxxxx 00000, Attention: Xxxxx X. Xxxxxx, Esq..
SECTION 15. Parties. This Agreement shall inure to the benefit of and be binding upon
Xxxxx Fargo Securities, the Transaction Entities and their respective successors. Nothing
expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm
or corporation, other than Xxxxx Fargo Securities, the Transaction Entities and their respective
successors and the controlling persons and officers and directors referred to in Sections 10 and 11
and their heirs and legal representatives, any legal or equitable right, remedy or claim under or
in respect of this Agreement or any provision herein contained. This Agreement and all conditions
and provisions hereof are intended to be for the sole and exclusive benefit of Xxxxx Fargo
Securities, the Transaction Entities and their respective successors, and said controlling persons
and officers and directors and their heirs and legal representatives, and for the benefit of no
other person, firm or corporation. No purchaser of Securities from Xxxxx Fargo Securities shall be
deemed to be a successor by reason merely of such purchase.
SECTION 16. Adjustments for Stock Splits. The parties acknowledge and agree that all
stock-related numbers contained in this Agreement shall be adjusted to take into account any stock
split, stock dividend or similar event effected with respect to the Securities.
SECTION 17. Governing Law and Time. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY
TIME.
SECTION 18. Effect of Headings. The Section and Exhibit headings herein are for
convenience only and shall not affect the construction hereof.
SECTION 19. Definitions. As used in this Agreement, the following terms have the
respective meanings set forth below:
“Applicable Time” means the time of each sale of any Securities pursuant to this
Agreement.
“Capital Stock” means any Common Stock, Preferred Stock or other capital stock of the
Company.
35
“XXXXX” means the Commission’s Electronic Data Gathering, Analysis and Retrieval
system.
“FINRA” means the Financial Industry Regulatory Authority.
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as
defined in Rule 433, relating to the Securities that (i) is required to be filed with the
Commission by the Company, (ii) is a “road show” that is a “written communication” within the
meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (iii) is
exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the
Securities or of the offering that does not reflect the final terms, and all free writing
prospectuses that are listed in Exhibit G hereto, in each case in the form filed or
required to be filed with the Commission or, if not required to be filed, in the form retained in
the Company’s records pursuant to Rule 433(g) under the Securities Act Regulations.
“Preferred Stock” means the Company’s preferred stock, par value $0.01 per share.
“Rule 163,” “Rule 164,” “Rule 172,” “Rule 405,” “Rule
415,” “Rule 424,” “Rule 424(b),” “Rule 430B,” and “Rule 433” refer to
such rules under the Securities Act Regulations.
“Xxxxxxxx-Xxxxx Act” means the Xxxxxxxx-Xxxxx Act of 2002 and the rules and
regulations promulgated thereunder or implementing the provisions thereof.
“Series A Preferred Stock” means the Company’s 7.375% Series A Cumulative Redeemable
Preferred Stock, par value $0.01 per share.
All references in this Agreement to financial statements and schedules and other information
that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and
all other references of like import) shall be deemed to mean and include all such financial
statements and schedules and other information that is incorporated by reference in the
Registration Statement or the Prospectus, as the case may be.
All references in this Agreement to the Registration Statement, the Prospectus or any
amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the
Commission pursuant to XXXXX; all references in this Agreement to any Issuer Free Writing
Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not
required to be filed with the Commission) shall be deemed to include the copy thereof filed with
the Commission pursuant to XXXXX; and all references in this Agreement to “supplements” to the
Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials
prepared in connection with any offering, sale or private placement of any Placement Securities by
Xxxxx Fargo Securities outside of the United States.
SECTION 20. Permitted Free Writing Prospectuses. Each of the Company and the
Operating Partnership represents, warrants and agrees that, unless it obtains the prior consent of
Xxxxx Fargo Securities, and Xxxxx Fargo Securities represents, warrants and agrees that, unless it
obtains the prior consent of the Company, it has not made and will not make any offer relating to
the Securities that would constitute an Issuer Free Writing Prospectus, or that would otherwise
36
constitute a “free writing prospectus,” as defined in Rule 405, required to be filed with the
Commission. Any such free writing prospectus consented to by Xxxxx Fargo Securities or by the
Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing
Prospectus.” The Company represents and warrants that it has treated and agrees that it will
treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in
Rule 433, and has complied and will comply with the requirements of Rule 433 applicable to any
Permitted Free Writing Prospectus, including timely filing with the Commission where required,
legending and record keeping. For the purposes of clarity, the parties hereto agree that all free
writing prospectuses, if any, listed in Exhibit G hereto are Permitted Free Writing
Prospectuses.
SECTION 21. Absence of Fiduciary Relationship. Each of the Transaction Entities,
severally and not jointly, acknowledges and agrees that:
(a) Xxxxx Fargo Securities is acting solely as agent (or as principal pursuant to a separate
underwriting or similar agreement described in Section 1) in connection with the public offering of
the Securities and in connection with each transaction contemplated by this Agreement and the
process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees
or any other party, on the one hand, and Xxxxx Fargo Securities, on the other hand, has been or
will be created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether or not Xxxxx Fargo Securities has advised or is advising the Company on other matters,
and Xxxxx Fargo Securities has no obligation to the Company with respect to the transactions
contemplated by this Agreement except the obligations expressly set forth in this Agreement;
(b) it is capable of evaluating and understanding, and understands and accepts, the terms,
risks and conditions of the transactions contemplated by this Agreement;
(c) Xxxxx Fargo Securities has not provided any legal, accounting, regulatory or tax advice
with respect to the transactions contemplated by this Agreement and it has consulted its own legal,
accounting, regulatory and tax advisors to the extent it has deemed appropriate;
(d) it is aware that Xxxxx Fargo Securities and its respective affiliates are engaged in a
broad range of transactions which may involve interests that differ from those of the Company and
Xxxxx Fargo Securities has no obligation to disclose such interests and transactions to the Company
by virtue of any fiduciary, advisory or agency relationship or otherwise; and
(e) it waives, to the fullest extent permitted by law, any claims it may have against Xxxxx
Fargo Securities for breach of fiduciary duty or alleged breach of fiduciary duty in connection
with the sale of Securities under this Agreement and agrees that Xxxxx Fargo Securities shall not
have any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of
such a fiduciary duty claim or to any person asserting a fiduciary duty claim on its behalf or in
right of it or the Company, employees or creditors of Company.
37
If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement between Xxxxx Fargo Securities, the Company and the Operating
Partnership in accordance with its terms.
Very truly yours, | ||||||
BIOMED REALTY TRUST, INC. | ||||||
By | /s/ R. Xxxx Xxxxxxx | |||||
Title: President | ||||||
BIOMED REALTY, L.P. | ||||||
By | /s/ R. Xxxx Xxxxxxx | |||||
Title: President |
CONFIRMED AND ACCEPTED, as of the date first above written: |
||||
XXXXX FARGO SECURITIES, LLC | ||||
By |
/s/ Xxxxxxx X. Xxxxxxxx | |||
|
||||
Xxxxxxx X. Xxxxxxxx Managing Director |
38